vadimezan: Clinical Trials

8 completed, 8 terminated, 2 withdrawn. 13 Phase 1, 4 Phase 2, 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 1	13	Completed 6, Terminated 6, Withdrawn 1
Phase 2	4	Completed 3, Withdrawn 1
Phase 3	2	Terminated 2

Follow vadimezan: new trials by email Literature Review of vadimezan trials Research Report on vadimezan

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma Docetaxel, ASA404 - Urothelial Carcinoma	Phase 2	Withdrawn	Hoosier Cancer Research Network		2010-06-01	2015-08-19
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function ASA404, DMXAA or DXAA - Metastatic Cancer	Phase 1	Terminated	Novartis Pharmaceuticals	7	2010-03-01	2020-12-09
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies ASA404, DMXAA, DXAA - Solid Tumor Malignancies	Phase 1	Terminated	Novartis Pharmaceuticals	54	2010-02-01	2011-09-02
Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer carboplatin, paclitaxel, vadimezan - Lung Cancer	Phase 2	Completed	Swiss Cancer Institute	17	2010-01-01	2013-04-10
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function ASA404 - Histologically-proven and Radiologically-confirmed Solid Tumors	Phase 1	Terminated	Novartis Pharmaceuticals	5	2010-01-01	2020-12-09
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors ASA404, Cetuximab, Carboplatin - Tumors	Phase 1	Withdrawn	University of California, San Francisco		2010-01-01	2013-05-13
An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 ASA404 - Metastatic Cancer With Impaired Renal Function, Metastatic Cancer With Normal Renal Function	Phase 1	Terminated	Novartis Pharmaceuticals	27	2010-01-01	2020-12-09
Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor Vadimezan™ - Solid Tumors	Phase 1	Terminated	Novartis Pharmaceuticals	17	2009-08-01	2011-09-02
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors vadimezan - Advanced or Recurrent Solid Tumors	Phase 1	Completed	Novartis Pharmaceuticals	9	2009-03-01	2020-12-09
A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors ASA404 - Advanced Solid Tumors	Phase 1	Terminated	Novartis Pharmaceuticals	7	2008-12-01	2017-02-14
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer ASA404, Placebo, docetaxel - Non-Small Cell Lung Cancer	Phase 3	Terminated	Novartis Pharmaceuticals	900	2008-12-01	2020-12-24
An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC) ASA404 - Non-small Cell Lung Cancer	Phase 1	Completed	Novartis Pharmaceuticals	15	2008-04-01	2020-12-09
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer ASA404, Placebo, carboplatin - Non-Small Cell Lung Cancer	Phase 3	Terminated	Novartis Pharmaceuticals	1285	2008-04-01	2020-12-24
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer AS1404 (DMXAA) - Prostate Cancer	Phase 2	Completed	Antisoma Research	70	2005-05-01	2009-01-30
Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer DMXAA in combination with carboplatin and paclitaxel - Non-Small Cell Lung Cancer	Phase 1 / Phase 2	Completed	Antisoma Research	105	2004-09-01	2009-01-30
Phase I Safety Study of DMXAA in Refractory Tumors DMXAA - Refractory Tumors	Phase 1	Completed	Antisoma Research	15	2003-05-01	2009-03-05
Study of DMXAA (Now Known as ASA404) in Solid Tumors DMXAA - Solid Tumors	Phase 1	Completed	Cancer Research UK	63	1996-05-01	2009-03-18
Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors vadimezan - Unspecified Adult Solid Tumor, Protocol Specific	Phase 1	Completed	University of Glasgow	3	1995-10-01	2013-12-19

Conditions studied

Carcinoma, Non-Small-Cell Lung (4)  ·  Neoplasm Metastasis (4)  ·  Neoplasms (3)  ·  Carcinoma, Transitional Cell (1)  ·  Lung Neoplasms (1)  ·  Prostatic Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (10)  ·  Antisoma Research (3)  ·  Cancer Research UK (1)  ·  Hoosier Cancer Research Network (1)  ·  Swiss Cancer Institute (1)  ·  University of California, San Francisco (1)  ·  University of Glasgow (1)

Countries

United States (7)  ·  Belgium (3)  ·  Italy (3)  ·  Japan (3)  ·  New Zealand (3)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Hungary (2)  ·  Poland (2)  ·  Spain (2)  ·  Switzerland (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Australia (1)

Top investigators

Mark McKeage (2)  ·  Dr Paul Thompson (1)  ·  Gordon J.S. Rustin, MD (1)  ·  Mark Jeffery (1)  ·  Martin Frueh, MD (1)  ·  Matthew Galsky, M.D. (1)  ·  Michael Jameson (1)  ·  Miklos Pless, MD (1)  ·  Oliver Gautschi, MD (1)  ·  Roberto Pili, MD (1)  ·  Sarita Dubey, MD (1)

Results publications

PMID 19387077, PMID 12799625, PMID 16551862, PMID 17356709, PMID 21835825, PMID 22263047, PMID 22633220